A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.
News|Videos|March 2, 2026
6 Hepatology Headlines You Missed in February 2026
Author(s)Abigail Brooks, MA
Fact checked by: Ryan Livingston
Catch up on new trial readouts, trends in hepatitis B birth dose vaccination, updates in a rare hepatic disease in honor of Rare Disease Day, and more.
Advertisement
Advertisement
February 2026 spotlighted a wave of innovation in genetic and translational hepatology, particularly in alpha-1 antitrypsin deficiency (AATD). Interim data for YOLT-202 demonstrated that a single in vivo base-editing dose could meaningfully increase functional AAT levels, while TSRA-196 earned both Fast Track and Orphan Drug designations from the US Food and Drug Administration (FDA), reinforcing growing regulatory support for one-time gene-editing strategies aimed at correcting the underlying PiZZ mutation.
Related to this article
Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.
In mice, liraglutide reduced steatosis through PPARα without needing iNKT cells, pointing to a possible GLP-1 RA plus PPARα combination.
A Cell Reports mouse study found hepatic steatosis fell without weight loss through separate iNKT cell and GLP-1 pathways.
HARMONY and SYMMETRY data show most early responders to efruxifermin 50 mg maintained fibrosis improvement through 96 weeks, with more responding late.
Volixibat reduced itch scores vs placebo in patients with PSC and moderate to severe pruritus in the phase 2b VISTAS trial presented at ACG 2026.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.
AASLD’s first Expert Practice Opinion adds EUS-guided biopsy and sets no INR or platelet thresholds.
Advertisement
Advertisement